Free Trial

Upstream Bio, Inc. (NASDAQ:UPB) Stock Rated "Hold" by Wall Street Analysts

Upstream Bio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts’ consensus is “Hold”: Of seven firms covering Upstream Bio, four rate it a buy, two a hold, and one a sell; the average 12-month price target is $29.67.
  • UPB opened at $3.23, near its 52-week low of $2.68 and well below its 52-week high of $33.68.
  • For the latest reported quarter, the company posted an adjusted loss of $0.73 per share, slightly better than estimates, and revenue of $0.77 million, above forecasts.
  • MarketBeat previews top five stocks to own in December.

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been assigned an average recommendation of "Hold" from the seven ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $29.67.

UPB has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Upstream Bio from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Truist Financial cut their price objective on shares of Upstream Bio to $25.00 and set a "buy" rating on the stock in a report on Tuesday, August 11th. Weiss Ratings raised shares of Upstream Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 17th. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Upstream Bio in a research report on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Upstream Bio from $8.00 to $9.00 and gave the stock a "neutral" rating in a research report on Friday, August 14th.

Check Out Our Latest Report on UPB

Upstream Bio Stock Performance

UPB stock opened at $3.23 on Friday. The firm has a market cap of $176.91 million, a P/E ratio of -1.11 and a beta of 1.60. Upstream Bio has a 1 year low of $2.68 and a 1 year high of $33.68. The stock has a 50-day simple moving average of $4.57 and a 200-day simple moving average of $8.80.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. The firm had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. On average, equities research analysts predict that Upstream Bio will post -2.84 EPS for the current year.

Institutional Trading of Upstream Bio

A number of hedge funds have recently made changes to their positions in UPB. BlackRock Inc. acquired a new position in shares of Upstream Bio during the second quarter valued at $25,973,000. Parkman Healthcare Partners LLC bought a new position in shares of Upstream Bio during the second quarter worth about $6,472,000. SEB Asset Management AB acquired a new stake in shares of Upstream Bio in the 1st quarter worth about $7,906,000. Hsbc Holdings PLC acquired a new stake in shares of Upstream Bio in the 1st quarter worth about $5,763,000. Finally, Walleye Capital LLC bought a new stake in Upstream Bio in the 2nd quarter valued at about $3,450,000.

About Upstream Bio

(Get Free Report)

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company's research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.

Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.

Further Reading

Analyst Recommendations for Upstream Bio (NASDAQ:UPB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Upstream Bio Right Now?

Before you consider Upstream Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.

While Upstream Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines